The impact of different antimicrobial exposures on the gut microbiome in the ARMORD observational study
Preprint
Peto L. et al, (2024)
The impact of different antimicrobial exposures on the gut microbiome in the ARMORD observational study
Preprint
Peto L. et al, (2024)
Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England
Journal article
Pessoa-Amorim G. et al, (2024), Trials
High-dose corticosteroid therapy in COVID-19: the RECOVERY trial - Authors' reply.
Journal article
Peto L. et al, (2024), Lancet, 403, 1339 - 1340
The impact of different antimicrobial exposures on the gut microbiome in the ARMORD observational study
Preprint
Peto L. et al, (2024)
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group None., (2024), Lancet Child Adolesc Health, 8, 190 - 200
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group None. et al, (2024), Nat Commun, 15
Community involvement in an outbreak - One year on for mpox.
Journal article
Cheyne A. et al, (2023), Clin Infect Dis
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group None., (2023), Lancet Diabetes Endocrinol, 11, 905 - 914
Methylprednisolone, intravenous immunoglobulin, tocilizimab or anakinra for children with Paediatric Inflammatory Multisystem Syndrome temporally associated with SARS CoV-2 (PIMS-TS, MIS-C) – report from a randomised, controlled, open-label, platform trial
Journal article
Landray M. et al, (2023), Lancet Child and Adolescent Health
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group. Electronic address: recoverytrial@ndph.ox.ac.uk None. and RECOVERY Collaborative Group None., (2023), Lancet, 401, 1499 - 1507
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Preprint
Horby PW. et al, (2023)
Randomised controlled trials for mpox in endemic countries.
Journal article
Rojek A. et al, (2023), Lancet Infect Dis
Microbial diversity and antimicrobial resistance in faecal samples from acute medical patients assessed through metagenomic sequencing.
Journal article
Yokoyama M. et al, (2023), PLoS One, 18
Virus Detection and Identification in Minutes Using Single-Particle Imaging and Deep Learning.
Journal article
Shiaelis N. et al, (2022), ACS Nano
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Preprint
Horby PW. et al, (2022)
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
Journal article
RECOVERY Collaborative Group None., (2022), Lancet, 400, 359 - 368
Establishing COVID-19 trials at scale and pace: Experience from the RECOVERY trial.
Journal article
Peto L. et al, (2022), Adv Biol Regul